Pharmaceutical company Mundipharma has acquired exclusive distribution rights to BioElectronics’ ActiPatch musculoskeletal therapy medical device in Australia and New Zealand.
BioElectronics’ ActiPatch Therapy is an over-the-counter (OTC) treatment for back pain and other musculoskeletal complaints.
The company secured pre-submission approval from the US Food and Drug Administration (US FDA) in May.
After review from the FDA, BioElectronics received guidance on 510(k) submission to obtain expanded market clearance for OTC treatment of musculoskeletal pain.
This would make ActiPatch available as a drug-free, safe, pain relief option for nearly 126 million Americans (one in two adults) who suffer from some form of musculoskeletal pain.
The ActiPatch device has already received FDA clearance for treating pain from knee osteoarthritis and plantar fasciitis.
BioElectronics sales and marketing vice president Keith Nalepka said: “We are pleased to have Mundipharma Australia’s professional support, training programs, clinical credentials, and medical and retail representatives educating physicians and pharmacists on the benefits of ActiPatch Therapy.
“It is essential for our growing sales and marketing portfolio to be supported and maintained by major healthcare marketers like Mundipharma.”
Mundipharma Australia and New Zealand managing director Jane Orr said the addition of ActiPatch to the company’s existing pain medications confirms its commitment to help clinicians manage pain with a multimodal approach, including non-drug therapies.
“Our education programs for healthcare professionals emphasize the importance of stepped multimodal pain management, so I’m delighted that we’re now able to offer ActiPatch,” Orr sai.
Established in 1952 by two physicians, Mundipharma is a privately-owned company with a network that is present across 120 countries and employs more than 8,600 people, while generating an annual income of $3.4bn.
The company claims to have a track record of building alliances to license develop and market medicines that improve patients’ lives, while providing attractive options to financially constrained healthcare systems.
It specializes in pain medicine and has grown significantly in three core therapeutic areas of respiratory, oncology and biosimilars.